These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 7905149)

  • 41. The biology of EBV infection in human epithelial cells.
    Tsao SW; Tsang CM; Pang PS; Zhang G; Chen H; Lo KW
    Semin Cancer Biol; 2012 Apr; 22(2):137-43. PubMed ID: 22497025
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Current Trends and Alternative Scenarios in EBV Research.
    Minarovits J; Niller HH
    Methods Mol Biol; 2017; 1532():1-32. PubMed ID: 27873264
    [TBL] [Abstract][Full Text] [Related]  

  • 43. EBV-NK cells interactions and lymphoproliferative disorders.
    Kanegane H; Yachie A; Miyawaki T; Tosato G
    Leuk Lymphoma; 1998 May; 29(5-6):491-8. PubMed ID: 9643562
    [TBL] [Abstract][Full Text] [Related]  

  • 44. EBV infection of T cells: potential role in malignant transformation.
    Kelleher CA; Dreyfus DH; Jones JF; Gelfand EW
    Semin Cancer Biol; 1996 Aug; 7(4):197-207. PubMed ID: 8946604
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Determination of nonendemic nasopharyngeal carcinoma by in situ hybridization for Epstein-Barr virus EBER1 RNA: sensitivity and specificity in cervical node metastases.
    Dictor M; Sivén M; Tennvall J; Rambech E
    Laryngoscope; 1995 Apr; 105(4 Pt 1):407-12. PubMed ID: 7536285
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Infection of human epithelial cell lines by Epstein-Barr virus. Interaction between epithelial cell and B lymphocyte.
    Takimoto T; Morishita K; Umeda R; Ogura H; Hatano M
    ORL J Otorhinolaryngol Relat Spec; 1984; 46(4):195-201. PubMed ID: 6087238
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Impaired long-term T cell immunity to Epstein-Barr virus in patients with nasopharyngeal carcinoma.
    Tamura S; Yamazaki A; Kunimoto M; Takemura K; Tabata T; Hinuma Y; Yoshie O
    Jpn J Cancer Res; 1992 May; 83(5):445-9. PubMed ID: 1319984
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Epstein-Barr virus (EBV) infection in infectious mononucleosis: virus latency, replication and phenotype of EBV-infected cells.
    Niedobitek G; Agathanggelou A; Herbst H; Whitehead L; Wright DH; Young LS
    J Pathol; 1997 Jun; 182(2):151-9. PubMed ID: 9274524
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Gastric carcinoma: monoclonal epithelial malignant cells expressing Epstein-Barr virus latent infection protein.
    Imai S; Koizumi S; Sugiura M; Tokunaga M; Uemura Y; Yamamoto N; Tanaka S; Sato E; Osato T
    Proc Natl Acad Sci U S A; 1994 Sep; 91(19):9131-5. PubMed ID: 8090780
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
    Niller HH; Wolf H; Minarovits J
    Autoimmunity; 2008 May; 41(4):298-328. PubMed ID: 18432410
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Introduction: Epstein-Barr virus and non-B cell tumours.
    Young LS
    Semin Cancer Biol; 1996 Aug; 7(4):163-4. PubMed ID: 8946599
    [No Abstract]   [Full Text] [Related]  

  • 52. Prolonged meningoencephalitis due to Epstein-Barr virus with favorable outcome in a young infant.
    Dagan R; Shahak E
    Infection; 1993; 21(6):400-2. PubMed ID: 8132372
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Physiologic concentrations of normal human plasma lipoproteins inhibit the immortalization of peripheral B lymphocytes by the Epstein-Barr virus.
    Chisari FV; Curtiss LK; Jensen FC
    J Clin Invest; 1981 Aug; 68(2):329-36. PubMed ID: 6267100
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Epstein-Barr virus infection in oral hairy leukoplakia: virus replication in the absence of a detectable latent phase.
    Niedobitek G; Young LS; Lau R; Brooks L; Greenspan D; Greenspan JS; Rickinson AB
    J Gen Virol; 1991 Dec; 72 ( Pt 12)():3035-46. PubMed ID: 1662695
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Epstein-Barr Virus Type 2 Infects T Cells and Induces B Cell Lymphomagenesis in Humanized Mice.
    Coleman CB; Lang J; Sweet LA; Smith NA; Freed BM; Pan Z; Haverkos B; Pelanda R; Rochford R
    J Virol; 2018 Nov; 92(21):. PubMed ID: 30089703
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Epstein-Barr virus carrier state: dominance of a single growth-transforming isolate in the blood and in the oropharynx of healthy virus carriers.
    Yao QY; Rowe M; Martin B; Young LS; Rickinson AB
    J Gen Virol; 1991 Jul; 72 ( Pt 7)():1579-90. PubMed ID: 1649896
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Epstein-Barr virus-associated carcinomas: facts and fiction.
    Herrmann K; Niedobitek G
    J Pathol; 2003 Feb; 199(2):140-5. PubMed ID: 12533825
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Epstein-Barr-virus infection and persistence: a B-cell marriage in sickness and in health.
    Young LS
    Lancet; 1999 Oct; 354(9185):1141-2. PubMed ID: 10513704
    [No Abstract]   [Full Text] [Related]  

  • 59. Epstein-Barr virus infection and human malignancies.
    Niedobitek G; Meru N; Delecluse HJ
    Int J Exp Pathol; 2001 Jun; 82(3):149-70. PubMed ID: 11488990
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Lymphotropic viruses, Epstein-Barr virus (EBV) and human T-cell lymphotropic virus-I (HTLV-I)/adult T-cell leukemia virus (ATLV), and HTLV-III/human immune deficiency virus (HIV) as etiological agents of malignant lymphoma and immune deficiency.
    Purtilo DT
    AIDS Res; 1986 Dec; 2 Suppl 1():S1-6. PubMed ID: 2881552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.